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FIGURE 2. Computed tomography scan showing passage of outflow graft under the superior vena cava. SVC, Superior vena cava; OG, outflow graft;
Ao, aorta; RA, right atrium; RPA, right pulmonary artery.
Surgical TechniquesSVC, and roof of the left atrium, rendering compression of
the SVC unlikely. As expected, we did not encounter SVC
syndrome and the CT scan did not show any compression.
At the time of VAD explant due to recovery or heart trans-
plant, we propose to either remove the whole graft or leave
a few millimeters of length behind the SVC if the adhesions
prohibit to its removal, thereby avoiding dissection and in-
jury to adjoining structures like the right pulmonary artery,
azygous vein, and SVC. Because the graft runs inside the
pericardium, the phrenic nerve remains protected. The tech-
nique is simple, easy, and reproducible.From the Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospi-
tal, Baltimore, Md.
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2009;138:1425-32.e1-3.Use of cryopreserved saphenous vein grafts in congenital
heart surgeryArman Kilic, MD, Duke E. Cameron, MD, and Luca A. Vricella, MD, Baltimore, MdThe use of saphenous vein grafts (SVGs) in congenital heart
surgery was reported as early as 1984.1 SVGs have several
advantages, including a low incidence of thrombosis and
infection and superior handling characteristics and hemo-
stasis, with acceptable patency rates. A potential hemody-
namic benefit of a competent valve also exists in cases in
which SVGs are used as right ventricle to pulmonary artery
(RV-PA) conduits.2 We report our experience with cryopre-
served SVGs as RV-PA conduits or modified Blalock-
Taussig shunts (MBTSs) in neonates and infants.gery c December 2012
TABLE 1. Patient characteristics and operative data
Variable Study population (n ¼ 36)
Patient
Median age 0.21 mo (2-54 d)
Male gender 20 (55.6%)
Median weight (kg) 2.9 (2.1-5.9)
Functional classification
Univentricular 24 (66.7%)
Biventricular 12 (33.3%)
Univentricular anomaly
HLHS 8 (22.2%)
UVH þ PS/PA 6 (16.7%)
Tricuspid atresia 4 (11.1%)
DILV/TGA 2 (5.6%)
PA/IVS 1 (2.8%)
Shunt endocarditis 1 (2.8%)
Biventricular anomaly
TOF/PA 3 (8.3%)
PA/MAPCAs 3 (8.3%)
Truncus arteriosus 3 (8.3%)
TOF/AVSD 1 (2.8%)
PS, RV dysfunction, TR 1 (2.8%)
DORV 1 (2.8%)
Operative
Procedure
MBTS 25 (69.4%)
RV-PA conduit 8 (22.2%)
Central shunt 3 (8.3%)
Approach
Median sternotomy 34 (94.4%)
Thoracotomy 2 (5.6%)
Redo cases 4 (11.1%)
Cardiopulmonary bypass 14 (38.9%)
Median graft size (mm)
MBTS 4 (3.5-4)
RV-PA conduit 5 (5-7)
Central shunt 5 (4-5)
Data presented as median (range) or numbers (%).HLHS, Hypoplastic left heart syn-
drome; UVH, univentricular heart disease; PS, pulmonary stenosis; PA, pulmonary
atresia; DILV, double inlet left ventricle; TGA, transposition of great arteries; IVS, in-
tact ventricular septum; TOF, tetralogy of Fallot; MAPCAs, major aortopulmonary
collateral arteries; AVSD, atrioventricular septal defect; RV, right ventricle; TR, tricus-
pid regurgitation; DORV, doublet outlet right ventricle; MBTS, modified Blalock-
Taussig shunt; RV-PA, right ventricle to pulmonary artery.
TABLE 2. Outcomes
Outcome Study population (n ¼ 36)
Follow-up
Median 6.3 mo
Range 2 d to 13.3 mo
Mortality
All-cause mortality
30-d 1 (2.8%)
In-hospital 4 (11.1%)
Interstage attrition 2 (5.6%)
Graft-related morbidity
Thrombosis 3 (8.3%)
Intraoperative 2 (5.6%)
Late 1 (2.8%)
Banding for pulmonary
overcirculation
2 (5.6%)
Stenosis 5 (13.9%)
RV-PA conduit 3 of 8 (37.5%)
MBTS 2 of 25 (8.0%)
Data presented as median and range or number (%). RV-PA,Right ventricle to pulmo-
nary artery; MBTS, modified Blalock-Taussig shunt.
Surgical TechniquesPATIENTS AND METHODS
A single-center, retrospective review was conducted of neonates and in-
fants undergoing palliation or correction of congenital heart disease with
a cryopreserved SVG as a conduit or shunt between October 2003 and
March 2011. The clinical, echocardiographic, and cardiac catheterization
data were reviewed. The anticoagulation protocol entailed systemic hepa-
rinization with 100U/kg, with no reversal. Outcomes included graft-related
mortality and complications, including thrombosis, bleeding, infection,
and significant stenosis, defined as greater than 50% diameter or requiring
percutaneous or operative intervention. The institutional review board ap-
proved the present study.
RESULTS
A total of 36 patients were included in the study. Of
these 36 patients, 11 (30.6%) were born prematurely andThe Journal of Thoracic and Car20 (55.6%) had a low birth weight; 34 (94.4%) were ne-
onates in the first 3 days of life (Table 1). The median pre-
operative weight was 2.9 kg. Functionally, most (66.7%;
n ¼ 24) had univentricular hearts. The most common
anomalies included hypoplastic left heart (22.2%;
n ¼ 8), univentricular heart disease with pulmonary steno-
sis or pulmonary atresia (16.7%; n ¼ 6), and tricuspid
atresia (11.1%; n ¼ 4).
The patients in the present study underwent placement of
a MBTS (69.4%; n ¼ 25), RV-PA conduit (22.2%; n ¼ 8),
or central shunt (8.3%; n ¼ 3; Table 1). Of the 25 MBTS
patients, 17 (68.0%) had a low birth weight. The approach
for most patients (94.4%; n ¼ 34) was through a median
sternotomy, with 2 (5.6%) undergoing thoracotomy. Two
patients (5.6%) had required extracorporeal membrane ox-
ygenation preoperatively. Four cases (11.1%) were reoper-
ations. Cardiopulmonary bypass was used in 14 patients
(38.9%).
The median follow-up was 6.3 months (range, 2 days to
13.3 months). Hospital mortality was 11.1% (4 patients),
with 1 death occurring before and 4 beyond 30 days
postoperatively. One patient with univentricular heart dis-
ease with pulmonary atresia experienced cardiac arrest on
postoperative day 2 and died (30-day mortality, 2.8%;
Table 2). An autopsy was declined by the parents. It is pos-
sible that the death could have been related to failure of the
patient’s shunt. An additional 3 patients died in-hospital: 1
of sepsis and malrotation on postoperative day 49 and 2 of
right ventricular dysfunction on postoperative day 65 and
72. In the patients surviving to discharge, the interstage
attrition was 6.3% (2 deaths). One patient died on postop-
erative day 45 of aspiration pneumonia. The second patientdiovascular Surgery c Volume 144, Number 6 1521
Surgical Techniqueshad tricuspid atresia with a restrictive pattern, who
presented in distress from an outside hospital and was given
extracorporeal membrane oxygenation but died on postop-
erative day 110.
Intraoperative thrombosis was observed in 2 patients
(5.6%) with isolated redo MBTS, both of whom underwent
immediate placement of a new SVG shunt (Table 2). One
patient (2.8%) developed thrombosis late after shunt place-
ment in the setting of postoperative dehydration after Nis-
sen fundoplication. Two patients (5.6%) required banding
for pulmonary overcirculation, one of whom was of low
birth weight.
Significant SVG stenosis developed in 5 patients (13.9%;
Table 2), including 3 with RV-PA conduits (37.5% of RV-
PA cases) that required stent placement. These stents were
placed for proximal angulation of the conduit, distal steno-
sis, and diffuse stenosis (each, n¼ 1). Other cases of signif-
icant stenosis included a distal right MBTS stenosis that
was augmented at the superior cavopulmonary anastomosis,
and a left MBTS that was stenosed at the previous augmen-
tation site of the left pulmonary artery.DISCUSSION
We have appreciated several advantages to using SVGs
in congenital heart surgery, and, in particular, in low-
birth-weight neonates, who constituted most of our study
population. From a technical aspect, SVGs are easier to
handle and have superior hemostasis than synthetic grafts.
Additionally, SVGs have lower thrombogenicity, an ad-
vantage even more relevant in these smaller grafts that
are prone to thrombosis.3 In addition to a low thrombosis
rate with SVGs, we have demonstrated a low rate of graft-
related mortality. Finally, when used as an MBTS, SVGs
were associated with a low rate of stenosis (8.0%) and
did not require interstage intervention. Our finding of
a lower rate of stenosis and intervention with MBTS ver-
sus RV-PA conduits was similar to the findings from
a multicenter randomized trial that compared these shunt1522 The Journal of Thoracic and Cardiovascular Surtypes (including synthetic grafts) in the Norwood
procedure.4
Despite these advantages, SVGs have a few drawbacks.
In general, SVGs have limited availability and significant
cost (each costs $4000 vs $1000 for synthetic grafts)
and can have an unpredictable diameter. Pulmonary over-
circulation requiring banding can occur owing to the
small size of the children, the unpredictable diameter of
the graft, and dilatation of the graft over time. We mea-
sure the inner diameter of the SVG with a Hegar dilator
and judge the potential for overcirculation by the usual
parameters, including diastolic blood pressure and oxy-
gen saturation. In our experience, we noted a high rate
of stenosis (37.5%) in cases in which SVGs were used
as RV-PA conduits. This rate was greater than what has
been reported in cases using synthetic RV-PA conduits.5
The reduced patency of SVGs as RV-PA conduits likely
results from several factors, including the unpredictabil-
ity of how the graft will lie and potential compression
of the graft by nearby structures. A ringed synthetic con-
duit might, therefore, be a better option in this position.
Given our data, we believe the best use for SVGs in con-
genital heart surgery are as MBTS in low-birth-weight
neonates.
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